INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17901, 21898, 'Pravastatin', 'Kidney Diseases', 'Pravastatin is partially eliminated by the kidney.  Drug and/or metabolite accumulation may occur in patients with significant renal impairment, which may increase the risk of adverse effects, including hepatic and musculoskeletal toxicities.  Therapy with pravastatin should be administered cautiously in patients with severely impaired renal function.  A lower initial dosage may be appropriate, accompanied by close clinical monitoring.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17902, 7403, 'Pravastatin', 'Cognitive Dysfunction', 'Cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) have been observed in patients receiving statins.  The reports are usually not serious, and reversible upon statin discontinuation.  Caution is recommended when using these agents in patients with cognitive impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17903, 7405, 'Pravastatin', 'Cognitive Dysfunction', 'Cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) have been observed in patients receiving statins.  The reports are usually not serious, and reversible upon statin discontinuation.  Caution is recommended when using these agents in patients with cognitive impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17904, 16265, 'Pravastatin', 'Cognitive Dysfunction', 'Cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) have been observed in patients receiving statins.  The reports are usually not serious, and reversible upon statin discontinuation.  Caution is recommended when using these agents in patients with cognitive impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17905, 21898, 'Pravastatin', 'Cognitive Dysfunction', 'Cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) have been observed in patients receiving statins.  The reports are usually not serious, and reversible upon statin discontinuation.  Caution is recommended when using these agents in patients with cognitive impairment.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17906, 7403, 'Pravastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17907, 7405, 'Pravastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17908, 16265, 'Pravastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17909, 21898, 'Pravastatin', 'Diabetes Mellitus', 'Increases in HbA1c and fasting serum glucose levels have been reported with the use of certain HMG-CoA reductase inhibitors.  Caution should be exercised when using these agents in diabetic patients and close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17910, 13086, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17911, 17831, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17912, 17832, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17913, 21425, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17914, 25669, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17915, 26928, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17916, 26929, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17917, 27124, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17918, 27125, 'Pramipexole', 'Hypotension', 'Dopamine agonists may impair the systemic regulation of blood pressure, with resultant orthostatic hypotension, especially during dose escalation.  Therapy with dopamine agonists should be monitored carefully in patients with Parkinson''s disease since they may have an impaired ability to respond to an orthostatic challenge, and also in patients receiving antihypertensive drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17919, 13086, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17920, 17831, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17921, 17832, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17922, 21425, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17923, 25669, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17924, 26928, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17925, 26929, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17926, 27124, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17927, 27125, 'Pramipexole', 'Neuroleptic Malignant Syndrome', 'The use of dopamine agonists is contraindicated in patients with neuroleptic malignant syndrome (NMS).  NMS is characterized by hyperthermia, muscle rigidity, altered mental status, irregular pulse or blood pressure, tachycardia, and diaphoresis.  The syndrome may rarely be precipitated by abrupt discontinuation of the dopamine agonist.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17928, 13086, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17929, 17831, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17930, 17832, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17931, 21425, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17932, 25669, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17933, 26928, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17934, 26929, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17935, 27124, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17936, 27125, 'Pramipexole', 'Psychotic Disorders', 'Ordinarily, patients with major psychotic disorder should not be treated with dopaminergic antiparkinson agents, because of the risk of exacerbating psychosis.  Hallucinations and psychotic-like behavior have been reported with dopaminergic medications.  In addition, certain medications used to treat psychosis may exacerbate the symptoms of Parkinson''s disease and may decrease the effectiveness of these drugs.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17937, 13086, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17938, 17831, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17939, 17832, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17940, 21425, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17941, 25669, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17942, 26928, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17943, 26929, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17944, 27124, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17945, 27125, 'Pramipexole', 'Kidney Failure, Chronic', 'Pramipexole is eliminated by the kidneys, and approximately 90% of the drug is excreted unchanged in the urine.  Renal insufficiency decreases the renal clearance and increases the half-life.  Therapy with pramipexole should be administered cautiously and at a reduced dose in patients with compromised renal function.  Pramipexole clearance is extremely low in dialysis patients, as a negligible amount of the drug is removed by it.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17946, 0, 'Pramlintide', 'Gastroparesis', 'The use of pramlintide is contraindicated in patients with a confirmed diagnosis of gastroparesis as it slows gastric emptying.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17947, 1510, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17948, 15194, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17949, 15198, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17950, 17726, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17951, 18443, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17952, 25135, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17953, 25136, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17954, 25137, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17955, 26607, 'Praziquantel', 'Cysticercosis', 'Since parasite destruction within the eye can cause irreparable lesions, ocular cysticercosis should not be treated with praziquantel.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17956, 1510, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17957, 15194, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17958, 15198, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17959, 17726, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17960, 18443, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17961, 25135, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17962, 25136, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17963, 25137, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17964, 26607, 'Praziquantel', 'Epilepsy', 'Praziquantel can exacerbate central nervous system pathology due to schistosomiasis.  As a general rule this drug should not be administered in individuals with a history of epilepsy or seizures and any other signs of potential central nervous system involvement such as subcutaneous nodules suggestive of cysticercosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17965, 1510, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17966, 15194, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17967, 15198, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17968, 17726, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17969, 18443, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17970, 25135, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17971, 25136, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17972, 25137, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17973, 26607, 'Praziquantel', 'Arrhythmias, Cardiac', 'Patients suffering from cardiac irregularities such as arrhythmias should be monitored during treatment with praziquantel.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17974, 1510, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17975, 15194, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17976, 15198, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17977, 17726, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17978, 18443, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17979, 25135, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17980, 25136, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17981, 25137, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17982, 26607, 'Praziquantel', 'Liver Failure', 'Caution should be exercised when administering praziquantel at the usual recommended doses in patients with moderate to severe liver impairment (Child Pugh class B and C).  Reduced metabolism of praziquantel may lead to considerably higher and longer lasting plasma concentrations of the unmetabolized drug.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17983, 929, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17984, 4136, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17985, 4586, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17986, 4587, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17987, 12996, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17988, 18253, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17989, 18254, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17990, 22272, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17991, 23833, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17992, 26424, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17993, 30132, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17994, 31130, 'Prilocaine', 'Methemoglobinemia', 'Prilocaine has induced methemoglobinemia resulting in respiratory distress and cyanosis.  Therapy with prilocaine topical should be administered cautiously to patients with or predisposed to methemoglobinemia.  If life-threatening or severe methemoglobinemia develops, methylene blue infused at a dosage of 1 to 2 mg/kg body weight will rapidly reverse or improve the condition, except in G-6-PD-deficient patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17995, 929, 'Prilocaine', 'Liver Failure', 'Prilocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of prilocaine.  Prilocaine is metabolized by the liver and to some extent by the kidney. The pharmacokinetic disposition of prilocaine is altered by changes in hepatic and renal function. Therapy with prilocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic and renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17996, 4136, 'Prilocaine', 'Liver Failure', 'Prilocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of prilocaine.  Prilocaine is metabolized by the liver and to some extent by the kidney. The pharmacokinetic disposition of prilocaine is altered by changes in hepatic and renal function. Therapy with prilocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic and renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17997, 4586, 'Prilocaine', 'Liver Failure', 'Prilocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of prilocaine.  Prilocaine is metabolized by the liver and to some extent by the kidney. The pharmacokinetic disposition of prilocaine is altered by changes in hepatic and renal function. Therapy with prilocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic and renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17998, 4587, 'Prilocaine', 'Liver Failure', 'Prilocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of prilocaine.  Prilocaine is metabolized by the liver and to some extent by the kidney. The pharmacokinetic disposition of prilocaine is altered by changes in hepatic and renal function. Therapy with prilocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic and renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (17999, 12996, 'Prilocaine', 'Liver Failure', 'Prilocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of prilocaine.  Prilocaine is metabolized by the liver and to some extent by the kidney. The pharmacokinetic disposition of prilocaine is altered by changes in hepatic and renal function. Therapy with prilocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic and renal function.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (18000, 18253, 'Prilocaine', 'Liver Failure', 'Prilocaine topical is absorbed through intact skin and mucosal membranes.  Prolonged exposure, large doses, and/or application to compromised skin or mucosa can result in elevated plasma concentrations of prilocaine.  Prilocaine is metabolized by the liver and to some extent by the kidney. The pharmacokinetic disposition of prilocaine is altered by changes in hepatic and renal function. Therapy with prilocaine topical should be administered cautiously and dosing modified for patients with compromised hepatic and renal function.', '2', '', 'DDInter', 0);
